Concern regarding classification of germline TP53 variants as likely pathogenic
To the Editor, We read with some concern the recent article in Human Mutation on the frequency of potentially actionable germline variants in the TP53 gene (de Andrade et al., 2019) . A prevalence estimate, including TP53 variants widely accepted as pathogenic/ likely pathogenic (LP), was reported as one carrier in 3, 476 individuals. However, an additional estimate of >1 in 500 was also proffered in the abstract, generated from the inclusion of several variants labelled as "likely pathogenic" using an arguably spurious classification system devised by and unique to the author, albeit that their classification as "likely pathogenic" for three common variants (p.N235S, p.V31I, and p.R290H) were juxtaposed with the term "controvertible."
We acknowledge this approach is distinct from and less stringent than that would be appropriate for clinical use. However, it is of great concern that readers interpreting TP53 variants, often found on Andrade as LP/P had the same effect the ratio would be close to 1.0 for all variants. If a common variant in Gnomad was only rarely associated with a typical Li Fraumeni pattern, perhaps as a chance finding, then the ratio would drop well below 1.0 providing evidence against causality. For the TCGA data, ratios of TCGA to gnomAD of less than 2.5-fold were considered against pathogenicity (in terms of high risk) and in IARC a ratio of below 0.5 was considered against. In reverse, ratios of case control from TCGA above 2-fold and above 1.5-fold in the IARC ratios were considered supportive. Third, for core binding domain missense variants a recent functional classification has been made available (Kotler et al., 2018) . We also obtained computational analyses of the pathogenic likelihood using the PolyPhen-2, SIFT, and Align GVGD algorithms. In addition, on the basis of the data outputs available, we also classified the variants using the recent ACMG guidelines. Examples of variants with gnomAD frequencies < n = 6
were also included to act as controls for our analyses.
The results of these analyses indicate that for the four variants, (c.848G>A; p.R283H, c.374C>T; p.T125M, c.655C>T; p.P219S, c.784G>A; p.G262S), that were classified as pathogenic by de Andrade et al. (2019), there is no case control data to support this conclusion with c.784G>A; p.G262S having three entries in gnomAD and 0 in IARC, insufficient to prove pathogenicity (see Table 1 ). In total, 15 of the LP and these four labeled pathogenic variants would be reclassified below LP on the basis of the Kotler data. individuals, very similar to our original estimate of one in 5,000 on the basis of a population series of very young breast cancers (Lalloo et al., 2003) .
Whilst we understand the authors' desire to document the frequencies of potentially actionable variants in TP53, it is of utmost importance that readers do NOT take their classification as support for actionability for cancer surveillance or to offer presymptomatic testing for variants that would certainly not be classified as LP or P using the recent American College of Medical Genetics guidelines (Richards et al., 2015) , which have also just been adopted in the United Kingdom (Ellard et al., 2018) as the standard for variant interpretation in the clinic.
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